Mapi - Pharma (Mapi - Pharma) Cash And Cash Equivalents : $4.50 Mil (As of Jun. 2015)

View and export this data going back to . Start your Free Trial

What is Mapi - Pharma Cash And Cash Equivalents?

Mapi - Pharma's quarterly cash and cash equivalents increased from Jun. 2014 ($0.00 Mil) to Dec. 2014 ($1.42 Mil) and increased from Dec. 2014 ($1.42 Mil) to Jun. 2015 ($4.50 Mil).

Mapi - Pharma's annual cash and cash equivalents declined from Dec. 2012 ($4.01 Mil) to Dec. 2013 ($2.31 Mil) and declined from Dec. 2013 ($2.31 Mil) to Dec. 2014 ($1.42 Mil).

Mapi - Pharma Cash And Cash Equivalents Historical Data

The historical data trend for Mapi - Pharma's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mapi - Pharma Cash And Cash Equivalents Chart

Mapi - Pharma Annual Data

Trend

Dec12

Dec13

Dec14

Cash And Cash Equivalents

4.01

2.31

1.42

Mapi - Pharma Semi-Annual Data
	Dec12	Dec13	Jun14	Dec14	Jun15
Cash And Cash Equivalents	4.01	2.31	-	1.42	4.50

Mapi - Pharma Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Mapi - Pharma (NAS:MAPI) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Mapi - Pharma Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Mapi - Pharma's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Mapi - Pharma (Mapi - Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mapi - Pharma Ltd (NAS:MAPI) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.mapi-pharma.com

Mapi - Pharma Ltd was incorporated under the laws of the State of Israel on January 29, 2008. It is a development stage pharmaceutical company, engaged in the development of high-barrier to entry and high-added value generic drugs that include complex active pharmaceutical ingredients or APIs, formulations and life cycle management or LCM products that target large markets. The Company is developing two LCM products for the treatment of multiple sclerosis and neuropathic pain. It is also developing a portfolio of approximately 13 complex APIs. Its LCM portfolio focuses on market product, consisting of Glatiramer Acetate Depot, a once-monthly injection for the treatment of MS, Pregabalin ER, extended release capsules for the treatment of neuropathic pain and epilepsy, and Risperidone LAI, a depot formulation of Risperdal Consta, expected to be developed under the abbreviated new drug application ANDA or 505(b)(2) shortened regulatory pathway. Its competitors in the generic pharmaceutical products and LCM markets includes Teva Pharmaceutical Industries Ltd.; Impax Laboratories, Inc.; Alkermes Plc.; Momenta Pharmaceuticals, Inc.; and Andrx Corporation; a private U.S. company. The Company's current patent portfolio contains approximately 20 patent applications for complex APIs, formulations, polymorphs, and routes of synthesis. Its operations are subject to many governmental regulations.